Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT)
NCT ID: NCT00564291
Last Updated: 2023-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
700 participants
OBSERVATIONAL
2007-01-31
2023-11-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Healthy volunteers
Examination with an OCT device
2
CSME secondary to diabetic retinopathy
No interventions assigned to this group
3
ARMD with CNV before and after therapy
Examination with an OCT device
4
ARMD atrophic
Examination with an OCT device
5
Retinal vein occlusion
Examination with an OCT device
6
retinitis pigmentosa
Examination with an OCT device
7
vitreoretinal proliferation
Examination with an OCT device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Examination with an OCT device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy subjects
18 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Bern
OTHER
Sebastian Wolf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sebastian Wolf
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sebastian Wolf, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Bern
Sebastian Wolf, MD PhD
Role: STUDY_DIRECTOR
University of Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dep. Ophthalmology, University Hospital Bern
Bern, , Switzerland
Klinik und Poliklinik für Augenheilkunde, University Bern
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lincke JB, Keller S, Amaral J, Zinkernagel MS, Schuerch K. Ciliary body length revisited by anterior segment optical coherence tomography: implications for safe access to the pars plana for intravitreal injections. Graefes Arch Clin Exp Ophthalmol. 2021 Jun;259(6):1435-1441. doi: 10.1007/s00417-020-04967-3. Epub 2020 Oct 19.
Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3334-7. doi: 10.1167/iovs.10-6097.
Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol. 2009 May;147(5):831-7. doi: 10.1016/j.ajo.2008.12.005. Epub 2009 Feb 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KEK 044/07
Identifier Type: -
Identifier Source: org_study_id